Moya Cordero Patricia, Ruiz-Aragón Jesús, Molina Linde Juan Máximo, Márquez-Peláez Sergio, Motiva Sánchez Virginia
Rev Chilena Infectol. 2013 Dec;30(6):591-7. doi: 10.4067/S0716-10182013000600002.
Tigecycline is indicated for the treatment of complicated skin infections, soft tissue and intraabdominal infections. Its use could be extended to community-acquired pneumonia (CAP) and hospital pneumonia (HN). The objective was to evaluate the efficacy and safety of tigecycline in the treatment of respiratory infections.
systematic review (2012). Databases used were MEDLINE, EMBASE, Cochrane Library, CRD and WOK. We identified clinical trials of adults with respiratory infection, treated with tigecycline. The quality of the studies was assessed using CASPe checklist.
We selected four clinical trials of high-moderate quality. Three studies with patients with CAP and a trial with HN patients. In patients with CAP, efficacy of tigecycline (88.6 to 90.6%) was higher than levofloxacin (85.3 to 87.2%). The non inferiority testing was statistically significant (p < 0.001). In the study of patients with HN tigecycline showed an efficiency of 67.9% versus 78.2% for imipenem/cilastatin. Main adverse effects were gastrointestinal.
The efficacy of tigecycline is non inferior than levofloxacin in patients with CAP, but less than imipenem in patients with HN. Tigecycline demonstrates noninferiority versus others tested antibiotics, and it shows a good safety profile.
替加环素适用于治疗复杂性皮肤感染、软组织感染和腹腔内感染。其应用范围可扩展至社区获得性肺炎（CAP）和医院获得性肺炎（HN）。目的是评估替加环素治疗呼吸道感染的有效性和安全性。
系统评价（2012年）。使用的数据库有MEDLINE、EMBASE、Cochrane图书馆、CRD和WOK。我们纳入了用替加环素治疗的成人呼吸道感染临床试验。使用CASPe清单评估研究质量。
我们选择了四项中高质量的临床试验。三项针对CAP患者的研究和一项针对HN患者的试验。在CAP患者中，替加环素的疗效（88.6%至90.6%）高于左氧氟沙星（85.3%至87.2%）。非劣效性检验具有统计学意义（p<0.001）。在HN患者的研究中，替加环素的有效率为67.9%，而亚胺培南/西司他丁为78.2%。主要不良反应为胃肠道反应。
替加环素在CAP患者中的疗效不劣于左氧氟沙星，但在HN患者中低于亚胺培南。替加环素与其他受试抗生素相比显示出非劣效性，且安全性良好。
